New studies have emerged demonstrating the safety of treating genitourinary syndrome of menopause (GSM) with topical estrogen in breast cancer survivors [28]; however, the safety of this treatment, particularly in patients with tumors that express estrogen receptors, remains controversial, requiring that the decision be individualized by considering the severity of symptoms and the risk of recurrence [29]. Here, ESR1 is linked to breast carcinoma.